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Background: Clinically, some patients would have false-negative results in the diagnosis of non-small cell lung
cancer (NSCLC) with pleural dissemination, losing their chances of prolonged survival from surgery. Hence, this
study aimed to clarify the benefit of radiofrequency ablation (RFA) for NSCLC with malignant pleural dissemination
that is detected during thoracoscopic lobectomy.
Methods: From July 2006, we started the application of RFA in combination with talc pleurodesis (R-TP) for pleural
disseminated NSCLCs diagnosed by thoracoscopy. Patients who underwent TP alone (from December 30, 2005 to
June 30, 2006) were retrospectively evaluated in compared with R-TP (from July 1, 2006 to June 30, 2008). Clinical
features were collected and compared to identify the difference in clinical outcomes between R-TP and TP alone.
After discharge (three months after surgery), tumor response to treatment was assessed, and follow-up results were
recorded to determine the perioperative and mid-time survival difference between the two groups.
Results: In our study, the two groups were comparable in age, sex, performance status (PS) score, tumor location,
and histological diagnosis. The incidence rate of intraoperative pleural dissemination was 5.98%, as diagnosed by
video-assisted thoracoscopy. All the surgeries were completed without conversion to open thoracotomy. Except for
the longer operation duration in the R-TP group (p < 0.001), there was no significant difference between the two
groups in terms of surgical features. Postoperatively, no mortality occurred in either group during hospital stay;
however, two patients from the R-TP group developed complications (9.52%). The complete and partial remission
rates in the R-TP group were 80% and 10%, respectively, and the stabilization rate was 10%. After the three-year
follow-up, the overall survival (OS) rates of the R-TP and TP groups were 14.29% and 0%, respectively. The median
survival and median tumor progression-free survival (PFS) periods were longer in the R-TP group than in the TP
group (OS: 19 months versus 12.5 months, p = 0.045; PFS: 9.5 months versus 5.5 months, p = 0.028).
Conclusions: The introduction of RFA to TP offered survival benefits to pleural disseminated NSCLC patients,
making it a potential alternative palliative treatment for local tumor. However, multicenter randomized controlled
trials are required to confirm these findings.
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Curative resection is the standard treatment for primary
(stage I–IIIa) non-small cell lung cancer (NSCLC) [1].
However, some cases diagnosed as “early-stage” cancer
before surgery are actually found to be pleural dissemi-
nated NSCLC during the operation. For patients with
such cases, surgical resection is not the treatment of
choice [2]. However, the prognosis would remain poor* Correspondence: lung2792@163.com
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reproduction in any medium, provided the oreven if the patient undergoes chemotherapy or radiothe-
rapy instead, with a survival rate close to stage IIIa–IIIb
cancer, as reported by Sawabata and colleagues [3]. Tra-
ditionally, talc pleurodesis (TP) is performed for the
control of pleural effusions associated with pleural dis-
seminated NSCLCs [4]. Although TP has been shown
to be safe and effective, the prognoses of patients who
undergo TP remain unchanged. Hence, new treatment
strategies are required to improve the survival of pa-
tients with advanced-stage NSCLC.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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frequency ablation (RFA) has been considered an alter-
native treatment of lung cancer [5] and shown to obtain
remarkable outcomes especially in patients with early-
stage cancer who could not tolerate standard surgery. In
the current literature, the reported complete remis-
sion (CR) rate, as well as the median survival time from
NSCLC patients underwent RFA were promising [6-9].
However, as for advanced lung cancers, whether RFA
could obtain the same remarkable outcomes as it did for
early-stage lesions remains unclear.
In this study, we hypothesized that RFA is beneficial to
patients with pleural disseminated NSCLC. Therefore,
we compared alternative (RFA combined with TP [R-TP])
and conservative therapies (TP alone) to determine whe-
ther R-TP would be technically safe and oncologically
beneficial in the treatment of advance NSCLCs.
Methods
At our institution, lung cancer is clinically staged by
thoracic computed tomography (CT), abdominal ultra-
sound, brain MRI, and isotopic bone scanning. Accor-
ding to the UICC system, In this study, the inclusion
criteria for VATS lobectomy are:
a. patients with clinical staged T1–T3N0M0 lung cancer;
b. patients without cancer history;
c. patients with no previous history of chest surgery;
d. patients with normal lung and heart function;
e. patients with an ASA score of I-III.
In case contraindications are found during thoracos-
copic exploration, a conversion from radical to palliative
surgery would be necessary. Conventionally, when pleu-
ral dissemination is verified during VATS, TP would
then be performed. Since July 1, 2006, TP was subs-
tituted by R-TP at our institution. The exclusion criteria
for R-TP included central tumors (within 3 cm of the
hilum) and refusal to undergo R-TP. In this retrospective
study, the clinical features and survival results of the
R-TP group (from July 1, 2006, to June 30, 2008) were
collected and compared with those of the TP group
(from December 30, 2005 to June 30, 2006) to identify
the difference between the two groups of patients.
Written informed consent was obtained from all the
patients before undergoing R-TP. The ethics committee
of Zhongshan hospital of Fudan university approved this
research and granted a waiver for individual patient con-
sent for those patients who were retrospectively evaluated.
Operation
Radiofrequency ablation
All the patients underwent a combination of epidural
and general anesthesia. During the operation, a double-lumen endotracheal tube was used to selectively deflate
a single lung, with a continuous positive airway pressure
of ten mmHg. The pleural tumor dissemination was ve-
rified by frozen sectioning. RFA was performed by using
the RITA system(RITA Medical Systems Inc, USA). The
deployment of the electrosurgical needle was staged
according to the size of the tumor. Under thoracoscopic
visual guidance, the probes were inserted 0.5 cm into
the primary tumor, and multiple electrodes were deplo-
yed to two centimeters within the tumor (sequentially to
three, four, and five centimeters). Thermal ablation was
extended for 15 minutes after the tumor temperature
reached 90°C. In the case of a large tumor (diameter lon-
ger than three centimeters), multiple repositioning and
reablation at different sites within the tumor were re-
quired to ensure ablation of the entire lesion. Then
six–eight grams of sterilized talc powder was sprayed
into the pleural cavity. With a chest tube for drain-
age, the surgery concluded with closure of the incisions
in layers. In TP, when the pathologists concurred on the
diagnosis of pleural dissemination, the procedure was to
spray six–eight grams of talcum powder into the pleural
cavity and close the incision, using a chest tube for
drainage.
Follow-up
Postoperatively, all the patients were followed up until
December 2010 by CT scans, abdominal type-B ultra-
sonic examination, and brain MRI inspection every three
months. An isotopic bone scan was obtained every six
months. Tumor response to treatment was assessed three
months after surgery, according to the modified Response
Evaluation Criteria in Solid Tumors.
Data collection and statistical analysis
The clinical data including patient demographics, tumor
characteristics, surgical features, and clinical outcomes
of both groups were collected from the clinical database
of the Thoracic Division of the Zhongshan Hospital,
Fudan University.
The information described earlier was recorded in
Excel for further processing. Statistical analysis was per-
formed with the SPSS software (version 17.0), using the
t test and chi-square test. Continuous variables were
compared using the Mann–Whitney test. A two-sided
p < 0.05 was considered statistically significant.
Results
Clinical features
From December 2005 to June 2008, 752 NSCLC patients
were eligible for VATS at our institution, 45 (5.98%) of
whom demonstrated pleural dissemination during the
operation. In our study, we performed R-TP for 21 pleu-
ral disseminated NSCLC patients until June 2008 and 24
Table 2 Perioperative characteristics
Perioperative characteristics R-TP TP p Value
Surgery duration (min) 110 (60–175) 50 (45–85) <0.001
Blood loss (mL) 80 (40–120) 60 (20–90) 0.227
Blood transfusion 0 0
Duration of drainage (days) 2.5 (2–3) 3(2–5) 0.143
Total drainage amount (mL) 105 (60–360) 80 (0–390) 0.069
Length of stay (days) 8 (7–14) 6 (4–16) 0.884
Mortality 0 0
Morbidity 2 0
The surgery duration includes intraoperative pathological consultation.
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controls. The incidence of unexpected pleural dissemin-
ation was close between R-TP and TP (21/339 versus
24/413, p = 0.832). In terms of patient demographics, the
two groups had comparable results in age, sex, PS score,
tumor volume, location, and histological diagnosis (listed
in Table 1).
All the surgeries were completed without conversion
to open thoracotomy. However, two postoperative com-
plications were recorded for R-TP: one patient develo-
ped pneumonia, which was later cured by conservative
therapy, and the other patient had a case of pneumo-
thorax but recovered after a three-day chest drainage.
We did not find similar cases for TP. The median hos-
pital stay was eight days (range, 7–14 days) for the R-TP
group and six days for the TP group (range, 4–16 days).
As for the surgical characteristics, the operation du-
ration in the R-TP group was longer than that in TP
group (Tables 1 and 2). After surgery, five patients (two
patients in TP and three patients in R-TP) were given
targeted therapy orally (Gefitinib or Erlotinib) due to gene
analysis for EGFR mutation, 28 patients (16 patients
in TP and 12 patients in R-TP) received chemother-
apy (platin-based chemotherapy, eg: Docetaxel plus
Cisplatin) for four-six cycles, and 12 patients (seven
patients in TP and five patients in R-TP) received suppor-
tive therapy including pain control, pleural drainage or
nutrition support.Table 1 Patient demographics
R-TP TP p Value
No. 21 24










AS 0 2 0.778
Tumor diameter (cm) 3.13 ± 1.01 2.80 ± 0.86
Postoperative treatment 0.846
Chemotherapy 10 18
Targeted therapy 2 3
Supportive therapy 9 3
AD adenocacinoma, SQ squamous carcinoma, AS adenosquamous carcinoma.Survival
In the R-TP group, 20 patients survived for three months
after the surgery and one patient died owing to systemic
infection after chemotherapy. The CT scans showed that
16 patients (80%) had complete remission, two (10%) had
partial remission, and two (10%) remained stable. The
total effective rate (CR + PR) was 90%.
After the three-year follow-up, tumor progression oc-
curred in 19 patients in the R-TP group, including six
brain metastasis, five bone metastasis, one contralateral
lung metastasis, one mediastinal lymph node metastasis,
and six local recurrences. The tumor progression rates
at years one, two, and three were 61.90%, 85.71%, and
90.48% respectively.
As for the TP group, no patient was free of tumor pro-
gression. Five cases of liver metastasis, eight cases of
bone metastasis, seven cases of brain metastasis, one
case of ipsilateral lung dissemination, and three cases of
multi-organ metastasis occurred during the three-year
follow-up. The tumor progression rate at years one, two,
and three were 75%, 91.67%, and 100%, respectively.
The median tumor progression-free survival time in
the R-TP group was longer than that in the TP group
(9.5 months versus 5.5 months, p = 0.028; Figure 1).
In the R-TP group, the overall survival rates at years
one, two, and three were 80.95%, 28.57%, and 14.29%,
respectively; the median survival period was 19 months.
In the TP group, the overall survival rates at years one,
two, and three were 54.17%, 20.83%, and 0%, respect-
ively, and the median survival period was 12 months.
Therefore, the median survival period was longer in the
R-TP group than in the TP group (19 months versus
12.5 months, p = 0.045; Figure 2).
Discussion
Concerning patients with early-stage NSCLC, surgical
resection is the standard treatment. Some large-sample
studies showed reasonable outcomes of lobectomy or
pneumonectomy for selected patients with early-stage
NSCLC [10]. Unfortunately, in cases of pleural dissemin-
ation, found via operation, surgery is not preferred and
Figure 1 Tumor progression free survival period (month).
Shen et al. BMC Surgery 2013, 13:19 Page 4 of 6
http://www.biomedcentral.com/1471-2482/13/19radiotherapy or chemotherapy is not effective either.
Given that pleural dissemination has been associated
with poor prognosis, it was upstaged to M1a in the se-
venth edition of the TNM staging classification [11].
Watanabe et al. [12] reported that more than half of all
patients who underwent exploratory thoracotomy were
found to have pleural dissemination. Hence, preventing
pleural dissemination remains a challenge for surgeons.
Since Dupuy et al. [5] first reported RFA for the treat-
ment of lung cancer in 2000, it has been shown to
obtain positive outcomes, encouraging more studies on
its application for lung cancer patients [13]. Previously,
the RAPTURE study reported the application ofFigure 2 Overall survival period (month).percutaneous RFA in inoperable early-stage lung can-
cer; the one- and two-year survival rates of the patients
were 92% and 73%, respectively [14], which were close
to the values obtained by surgical resection. Indeed,
RFA is an alternative treatment for patients with early-
stage cancer who are inoperable. Based on these find-
ings, we explored its further application in advanced
lung cancer.
In our study, the overall survival rates at years one,
two, and three were 80.95%, 28.57%, and 14.29%, re-
spectively, and the tumor progression-free and overall
survival rates were higher in the R-TP group, indicating
a better prognosis than that of the patients who
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combination with TP did not increase the risks of peri-
operative morbidity and mortality according to our data.
Therefore, the combined R-TP treatment of pleural dis-
seminated NSCLC does not increase the risks of higher
morbidity.
According to the review by Zhu et al. [15], the com-
plete tumor control rates by RFA ranged from 38–97%.
Simon et al. [13] reported that the results were poorer in
lesions that measured ≥ three centimeters. The total ef-
fective rate was 90% in the R-TP group in our research.
The relatively high CR rate was realized using VATS,
which allowed precise tumor localization without inter-
ference from respiration and damage caused by puncture
needles. As for large tumors, multiple repositioning of
the needle in different sites within the tumor was re-
quired to ensure complete ablation of the lesion.
It was concluded that NSCLC patients with malignant
pleural diffusion would not benefit from tumor resection
[2]. However, NSCLC patients who underwent partial
resection combined with parietal pleurectomy or intra-
thoracic hyperthermo-chemotherapy [16-18] had good
prognosis. The application of the combined treatment
modality is restricted to operable patients. In contrast,
video-assisted RFA can be applied more widely and
preserves normal lung tissue maximally [19]. Goldberg
et al. [20] used an animal model to demonstrate that
normal lung tissue rapidly heals from thermal injury.
Thus, for NSCLC patients with pleural dissemination,
especially those with poor lung function, video-assisted
RFA combined with pleurodesis is a potential alternative
treatment that yields more benefits in a single surgical
setting.
In our experience, when a tumor is close to large ves-
sels, the blood may absorb a great amount of heat and
impair the effectiveness of RFA. In case the lesion is
close to the hilum, RFA may cause complications such
as bronchopleural fistula. In these conditions, RFA is not
recommended, but rather refined techniques are re-
quired to overcome these difficulties.
The common complications of CT-guided percutan-
eous RFA include pneumothorax and pleural effusion
(range, 15.2%–55.6%), which were usually self-limiting.
Approximately 3.3–38.9% of the patients required chest
tube insertion for drainage [15,21]. In our study, only
two complications (9.52%) occurred in the R-TP group.
Although the study was based on small population, the
relatively low incidence of complication suggested that
thoracoscopic guidance could be considered as a safe
and easy alternative to conventional therapy. The elec-
trode tract bleeding was controlled by increasing the
output power of the RITA system for electric coagu-
lation homeostasis; in case of small branches of pulmo-
nary artery bleeding, we used carbasus to stanch theblood. These manipulations decreased the risk of com-
plications caused by percutaneous RFA such as pneumo-
thorax and hemothorax. Our study showed that the
perioperative characteristics did not differ between the
R-TP and TP groups. One patient had pneumonia, and
another complained of emptysis after surgery due to the
large tumor near the central airway. The latter was even-
tually cured with hemostasis. Furthermore, thoracosco-
pic RFA did not increase the surgery-related risk and the
period of postoperative hospital stay.
Conclusions
In summary, this study evaluated 45 consecutive patients
with pleural disseminated NSCLC. The perioperative
and long-term follow-up results verified that the video-
assisted RFA was a safe, feasible, and effective treatment
for selected NSCLC patients with pleural dissemination,
as well as an alternative palliative treatment for local
tumor. However, further prospective studies on the role
of RFA in the multimodality treatment for inoperable
patients are necessary.
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